TABLE 2

Subjects Characteristics

9vHPV Vaccine
Subjects in population, n15875
Sex, n (%)
 Male3225 (20.3)
 Female12650 (79.7)
Age, n (%)
 9–15 y5308 (33.4)
 16–17 y608 (3.8)
 18–26 y9959 (62.7)
Mean (SD)18.4 (5.1)
Median (range)20.0 (9–26)
Race, n (%)
 Asian2213 (13.9)
 Black718 (4.5)
 Othera3628 (22.9)
 White9316 (58.7)
Regionb
 Africa215 (1.4)
 Asia-Pacific2112 (13.3)
 Europe5660 (35.7)
 Latin America4186 (26.4)
 North America3702 (23.3)
  • a Mostly multiracial subjects.

  • b Study participants were from 31 countries (Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Denmark, Finland, Germany, Hong Kong, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, New Zealand, Norway, Peru, the Philippines, Poland, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, and the United States [including Puerto Rico]).